血管生成在肿瘤发生、增殖、侵袭和转移的全程中都扮演着重要角色，以肿瘤血管生成信号通路中的关键分子为靶点开发抗肿瘤药物是目前药物研发的热点。肿瘤相关的血管生成信号通路包括VEGF/VEEFR、血管生成素及其受体、血小板源生长因子及其受体、Delta-like Ligand/Notch、成纤维细胞生长因子及其受体、肝细胞生长因子及其受体、转化生长因子及其受体、内皮素系统等。与肿瘤血管生成通路相关的药物中，贝伐单抗（bevacizumab)、索拉非尼(sorafenib)、舒尼替尼(sunitinib)等药物已经获得FDA的批准，在直肠癌、肾癌、非小细胞肺癌、肝癌、胃肠间质瘤等肿瘤患者中取得了良好效果，数十种尚未被FDA批准的抗血管生成药物也正在全球进行各期临床试验。本文总结肿瘤血管生成信号通路的基础研究及其相关药物临床转化的研究进展。

Angiogenesis plays an important role in almost all aspects of tumor biology, including the occurrence, proliferation, progression and metastasis. Accordingly, inhibition of tumor angiogenesis through targeting key molecules in the signal pathways involved in angiogenesis has become a subject of extensive and intensive research in the field of anti-tumor drug development. Amongst these molecules are VEGF/VEGFR, Angiopoietin(Ang)/Tie, platelet derived growth factor, fibroblast growth factor, Delta-like Ligand (DLL4)/Notch, transforming growth factor β, hepatocyte growth factor, and endothelin. A few drugs, such as bevacizumab, sorafinib and sunitinib, targeting angiogenic molecules have been approved by FDA and their clinical use has generated satisfactory results in treating colorectal cancer, renal cell carcinoma, non small cell lung cancer, hepatocellular carcinoma and gastrointestinal stroma tumor; dozens of unapproved drugs in this class are under evaluation in clinical trials. This article aims to review recent advances in both bench-top and translational research on essential signal pathways involved in tumor angiogenesis.